$CDNA
CareDx, Inc.

2020 Q2 Form 10-Q Financial Statement

#000121723420000146 Filed on August 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $41.80M $31.45M
YoY Change 32.9% 76.48%
Cost Of Revenue $15.03M $11.51M
YoY Change 30.52% 59.73%
Gross Profit $26.78M $19.94M
YoY Change 34.27% 87.85%
Gross Profit Margin 64.06% 63.4%
Selling, General & Admin $24.45M $19.16M
YoY Change 27.64% 67.16%
% of Gross Profit 91.31% 96.06%
Research & Development $13.13M $7.630M
YoY Change 72.07% 118.25%
% of Gross Profit 49.03% 38.26%
Depreciation & Amortization $1.630M $1.220M
YoY Change 33.61% 23.23%
% of Gross Profit 6.09% 6.12%
Operating Expenses $52.60M $26.79M
YoY Change 96.39% 69.26%
Operating Profit -$10.80M -$6.844M
YoY Change 57.85% 31.39%
Interest Expense $21.00K $300.0K
YoY Change -93.0% -170.75%
% of Operating Profit
Other Income/Expense, Net $3.915M -$1.223M
YoY Change -420.11% -86.76%
Pretax Income -$6.888M -$8.067M
YoY Change -14.62% -44.15%
Income Tax -$300.0K -$200.0K
% Of Pretax Income
Net Earnings -$6.558M -$7.847M
YoY Change -16.43% -44.2%
Net Earnings / Revenue -15.69% -24.95%
Basic Earnings Per Share -$0.15 -$0.19
Diluted Earnings Per Share -$0.15 -$0.19
COMMON SHARES
Basic Shares Outstanding 44.71M shares 42.13M shares
Diluted Shares Outstanding 44.71M shares 42.13M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $211.4M $43.50M
YoY Change 385.98% 168.52%
Cash & Equivalents $211.4M $43.47M
Short-Term Investments
Other Short-Term Assets $4.300M $2.500M
YoY Change 72.0% 56.25%
Inventory $8.741M $5.341M
Prepaid Expenses
Receivables $27.11M $17.05M
Other Receivables $0.00 $0.00
Total Short-Term Assets $251.5M $68.32M
YoY Change 268.17% 123.45%
LONG-TERM ASSETS
Property, Plant & Equipment $7.313M $3.508M
YoY Change 108.47% 48.64%
Goodwill $23.90M $10.20M
YoY Change 134.31% -15.04%
Intangibles $44.36M $45.60M
YoY Change -2.74% 31.2%
Long-Term Investments
YoY Change
Other Assets $1.000M $300.0K
YoY Change 233.33% 50.0%
Total Long-Term Assets $93.20M $74.58M
YoY Change 24.95% 51.28%
TOTAL ASSETS
Total Short-Term Assets $251.5M $68.32M
Total Long-Term Assets $93.20M $74.58M
Total Assets $344.7M $142.9M
YoY Change 141.24% 78.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.675M $7.380M
YoY Change 17.55% 112.07%
Accrued Expenses $16.40M $12.80M
YoY Change 28.12% 91.04%
Deferred Revenue $3.731M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $0.00
YoY Change
Total Short-Term Liabilities $56.94M $28.60M
YoY Change 99.1% 101.75%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.614M $18.80M
YoY Change -91.41% -4.57%
Total Long-Term Liabilities $1.614M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.94M $28.60M
Total Long-Term Liabilities $1.614M $0.00
Total Liabilities $83.98M $49.70M
YoY Change 68.96% 80.64%
SHAREHOLDERS EQUITY
Retained Earnings -$346.2M
YoY Change
Common Stock $612.3M $425.4M
YoY Change 43.92% 32.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $260.8M $93.17M
YoY Change
Total Liabilities & Shareholders Equity $344.7M $142.9M
YoY Change 141.24% 78.9%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$6.558M -$7.847M
YoY Change -16.43% -44.2%
Depreciation, Depletion And Amortization $1.630M $1.220M
YoY Change 33.61% 23.23%
Cash From Operating Activities $24.10M $3.580M
YoY Change 573.18% -290.43%
INVESTING ACTIVITIES
Capital Expenditures -$3.980M -$1.150M
YoY Change 246.09% -79.46%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$16.04M
YoY Change -100.0%
Cash From Investing Activities -$3.980M -$17.18M
YoY Change -76.83% 206.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 158.7M -270.0K
YoY Change -58877.78% -105.31%
NET CHANGE
Cash From Operating Activities 24.10M 3.580M
Cash From Investing Activities -3.980M -17.18M
Cash From Financing Activities 158.7M -270.0K
Net Change In Cash 178.8M -13.87M
YoY Change -1389.26% 475.52%
FREE CASH FLOW
Cash From Operating Activities $24.10M $3.580M
Capital Expenditures -$3.980M -$1.150M
Free Cash Flow $28.08M $4.730M
YoY Change 493.66% 27.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001217234
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P8Y2M
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36536
dei Entity Registrant Name
EntityRegistrantName
CAREDX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3316839
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Tower Place
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
287-2300
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CDNA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48963851 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211409000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38223000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27111000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24057000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
8741000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
6014000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4286000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3628000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
251547000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
71922000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7313000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4430000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16416000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4730000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
44356000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
45541000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
23857000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
23857000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
253000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
256000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000 USD
CY2020Q2 us-gaap Assets
Assets
344742000 USD
CY2019Q4 us-gaap Assets
Assets
151736000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8675000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5506000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11089000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12484000 USD
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16682000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16838000 USD
CY2020Q2 cdna Contract With Customer Liability Current Advance Payment Cares Act
ContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct
20496000 USD
CY2019Q4 cdna Contract With Customer Liability Current Advance Payment Cares Act
ContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct
0 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
56942000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34828000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1313000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1973000 USD
CY2020Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1681000 USD
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6607000 USD
CY2020Q2 cdna Deferred Payments For Intangible Assets Noncurrent
DeferredPaymentsForIntangibleAssetsNoncurrent
5400000 USD
CY2019Q4 cdna Deferred Payments For Intangible Assets Noncurrent
DeferredPaymentsForIntangibleAssetsNoncurrent
5207000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17025000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2370000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1614000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1751000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
83975000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
52736000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48862296 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48862296 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42498430 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42498430 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
47000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
42000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
612228000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
437976000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5314000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5205000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346194000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333813000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
260767000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99000000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344742000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151736000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41801000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31454000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80181000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57436000 USD
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
15025000 USD
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
11512000 USD
us-gaap Cost Of Revenue
CostOfRevenue
27417000 USD
us-gaap Cost Of Revenue
CostOfRevenue
21245000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
26776000 USD
CY2019Q2 us-gaap Gross Profit
GrossProfit
19942000 USD
us-gaap Gross Profit
GrossProfit
52764000 USD
us-gaap Gross Profit
GrossProfit
36191000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23142000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13129000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7630000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13244000 USD
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12134000 USD
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10644000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23857000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17569000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12316000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8512000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22319000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17618000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
37579000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
26786000 USD
us-gaap Operating Expenses
OperatingExpenses
69318000 USD
us-gaap Operating Expenses
OperatingExpenses
48431000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-255000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-172000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10803000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6844000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-16554000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12240000 USD
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
21000 USD
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
300000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
117000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
642000 USD
CY2020Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-664000 USD
CY2019Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1351000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1069000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4360000 USD
CY2020Q2 cdna Relief Fund Provider Cares Act
ReliefFundProviderCARESAct
4813000 USD
CY2019Q2 cdna Relief Fund Provider Cares Act
ReliefFundProviderCARESAct
0 USD
cdna Relief Fund Provider Cares Act
ReliefFundProviderCARESAct
4813000 USD
cdna Relief Fund Provider Cares Act
ReliefFundProviderCARESAct
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-318000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-246000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3915000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1223000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3543000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3964000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6888000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8067000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13011000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16204000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-330000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-220000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-630000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-826000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6558000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7847000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12381000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Net Income Loss
NetIncomeLoss
-15378000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44708037 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42132396 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43765732 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41873337 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44708037 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42132396 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43765732 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41873337 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6558000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7847000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12381000 USD
us-gaap Net Income Loss
NetIncomeLoss
-15378000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1596000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-109000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-793000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4962000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7916000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12490000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16171000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
699000 USD
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1507000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
66000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
155000 USD
CY2020Q1 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
6299000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4200000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1705000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5823000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
101384000 USD
CY2020Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2030000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
58000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1962000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6320000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1596000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6558000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
260767000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
95928000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
341000 USD
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2378000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
51000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1365000 USD
CY2019Q1 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
2569000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6001000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-724000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7531000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
95622000 USD
CY2019Q2 cdna Change In Estimated Offering Costs
ChangeInEstimatedOfferingCosts
50000 USD
CY2019Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1597000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
52000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1405000 USD
CY2019Q2 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
612000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4938000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7847000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
93166000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12381000 USD
us-gaap Net Income Loss
NetIncomeLoss
-15378000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10676000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11045000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1069000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4360000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3249000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2380000 USD
cdna Loss On Write Off Of Fixed Assets
LossOnWriteOffOfFixedAssets
0 USD
cdna Loss On Write Off Of Fixed Assets
LossOnWriteOffOfFixedAssets
150000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1256000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
201000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
266000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1900000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5956000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2682000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
551000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
665000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
219000 USD
cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-721000 USD
cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-418000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2569000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3285000 USD
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-1283000 USD
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-1881000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1724000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1208000 USD
cdna Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act
IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct
-20496000 USD
cdna Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act
IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct
0 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
630000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
517000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21043000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2291000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
16037000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2250000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1124000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3434000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
561000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5684000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17722000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
602000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
341000 USD
cdna Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
3537000 USD
cdna Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
3975000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
304000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
105000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2117000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2769000 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
90000 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
84000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
116000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
157961000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-960000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-137000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-111000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
173183000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21084000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38479000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64808000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
211662000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43724000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211409000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38223000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
253000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
256000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
211662000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38479000 USD
CY2018Q1 cdna Number Of Renal Transplant Patients
NumberOfRenalTransplantPatients
1600 patient
CY2020Q2 cdna Number Of Transplant Centers Offering Remo Tra C
NumberOfTransplantCentersOfferingRemoTraC
150 center
CY2020Q2 cdna Number Of Patients Enrolled In Remo Tra C
NumberOfPatientsEnrolledInRemoTraC
4000 patient
CY2020Q2 cdna Number Of Mobile Phlebotomists
NumberOfMobilePhlebotomists
10000 phlebotomist
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346200000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211400000 USD
CY2020Q2 cdna Cares Act Centers For Medicare And Medicaid Services Proceeds From Advance Payment
CARESActCentersForMedicareAndMedicaidServicesProceedsFromAdvancePayment
20500000 USD
CY2020Q2 cdna Cares Act Medicare Fee For Service Reimbursements Proceeds Initial Tranche
CARESActMedicareFeeForServiceReimbursementsProceedsInitialTranche
4800000 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reclassifications and Changes in Presentation</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts have been reclassified to conform with the current period presentation, including: (i) combined presentation of cost of testing services, cost of product and cost of digital, and (ii) separate presentation of gross profit. These reclassifications had no effect on the reported results of operations.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of digital revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended June 30, 2020 and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, approximately 56% and 54%, respectively, of total revenue was derived from Medicare. For the six months ended June 30, 2020 and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, approximately 55% and 54%, respectively, of total revenue was derived from Medicare. No other payers or customers represented more than 10% of total revenue for these periods.</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, approximately 29% and 36%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable on either June 30, 2020 or December 31, 2019.</span></div>
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6558000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7847000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12381000 USD
us-gaap Net Income Loss
NetIncomeLoss
-15378000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44708037 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42132396 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43765732 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41873337 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4751319 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4751319 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4464528 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4464528 shares
CY2019Q2 us-gaap Goodwill
Goodwill
10200000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
23900000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
59816000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13029000 USD
CY2020Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3681000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13029000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43106000 USD
CY2020Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
61066000 USD
CY2020Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3681000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
44356000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
57713000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10719000 USD
CY2019Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3556000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43438000 USD
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
59816000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10719000 USD
CY2019Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3556000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
45541000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2409000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4584000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4566000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4566000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4566000 USD
CY2020Q2 cdna Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
22415000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43106000 USD
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4762000 USD
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1236000 USD
CY2020Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1949000 USD
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1189000 USD
CY2020Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2030000 USD
CY2019Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3589000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
8741000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
6014000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3731000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3686000 USD
CY2020Q2 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
4912000 USD
CY2019Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
3068000 USD
CY2020Q2 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
1042000 USD
CY2019Q4 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
2098000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1733000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3017000 USD
CY2020Q2 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
640000 USD
CY2019Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
835000 USD
CY2020Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
726000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
547000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
983000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
810000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1587000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
766000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1328000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2011000 USD
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16682000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16838000 USD
CY2020Q2 cdna Cares Act Centers For Medicare And Medicaid Services Proceeds From Advance Payment
CARESActCentersForMedicareAndMedicaidServicesProceedsFromAdvancePayment
20500000 USD
CY2020Q1 cdna Operating Lease Right Of Use Asset Increase
OperatingLeaseRightOfUseAssetIncrease
13000000.0 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16400000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1700000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17000000.0 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1114000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
455000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
2233000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
905000 USD
CY2020Q2 cdna Finance Lease Cost
FinanceLeaseCost
51000 USD
CY2019Q2 cdna Finance Lease Cost
FinanceLeaseCost
55000 USD
cdna Finance Lease Cost
FinanceLeaseCost
104000 USD
cdna Finance Lease Cost
FinanceLeaseCost
110000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
1165000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
510000 USD
us-gaap Lease Cost
LeaseCost
2337000 USD
us-gaap Lease Cost
LeaseCost
1015000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y6M25D
CY2020Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M2D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2020Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.062
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 USD
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
2400000 USD
CY2019Q2 cdna Stock Issued During Period Shares Cashless Warrants Exercises In Period
StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod
15000000 shares
cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
94000 shares
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
105000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1699000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
71000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3522000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3964000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2811000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2909000 USD
CY2020Q2 cdna Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
0 USD
CY2020Q2 cdna Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
13267000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
176000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
100000 USD
cdna Number Of Warrants Exercised Cashless Basis
NumberOfWarrantsExercisedCashlessBasis
96000000 shares
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28172000 USD
CY2014Q2 cdna Number Of Milestone Payments
NumberOfMilestonePayments
6 milestone_payment
CY2020Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 USD
CY2019Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 USD
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 USD
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000 USD
CY2020Q2 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
0 shares
cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
272000 shares
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000 USD
CY2020Q2 cdna Number Of Warrants Exercised Cashless Basis
NumberOfWarrantsExercisedCashlessBasis
0 shares
cdna Number Of Warrants Exercised Cashless Basis
NumberOfWarrantsExercisedCashlessBasis
34000 shares
cdna Stock Issued During Period Shares Cashless Warrants Exercises In Period
StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod
24000 shares
CY2019Q2 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
24000 shares
CY2019Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
100000 USD
CY2019Q2 cdna Number Of Warrants Exercised Cashless Basis
NumberOfWarrantsExercisedCashlessBasis
40000000 shares
cdna Stock Issued During Period Shares Cashless Warrants Exercises In Period
StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod
40000000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
504775 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2609848 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1699549 shares
cdna Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services
ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices
6083 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
821204 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
660739 shares
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Including Prior Period Shares Adjustment
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossIncludingPriorPeriodSharesAdjustment
660739 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.89
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
246830 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.49
cdna Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
143603 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
86200 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65536 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65536 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
18328 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
18328 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.58
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1029965 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2939893 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.86
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3300000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000000.0 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000000.0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12000000.0 USD
CY2020Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
1149000 shares
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
13.05
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y9M3D
CY2020Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
25774000000 USD
CY2020Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
1658000 shares
CY2020Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
22.57
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y10M20D
CY2020Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
21326000000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2807000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
47100000000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6417000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4992000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10676000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11045000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41801000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31454000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80181000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57436000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7313000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4430000 USD

Files In Submission

Name View Source Status
0001217234-20-000146-index-headers.html Edgar Link pending
0001217234-20-000146-index.html Edgar Link pending
0001217234-20-000146.txt Edgar Link pending
0001217234-20-000146-xbrl.zip Edgar Link pending
caredx-outsidedirector.htm Edgar Link pending
cdna-20200630.htm Edgar Link pending
cdna-20200630.xsd Edgar Link pending
cdna-20200630x10qxexx3.htm Edgar Link pending
cdna-20200630x10qxexx31.htm Edgar Link pending
cdna-20200630x10qxexx32.htm Edgar Link pending
cdna-20200630_cal.xml Edgar Link unprocessable
cdna-20200630_def.xml Edgar Link unprocessable
cdna-20200630_htm.xml Edgar Link completed
cdna-20200630_lab.xml Edgar Link unprocessable
cdna-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending